{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=61", "query": { "condition": "Lymphoma", "page": 61 }, "page_size": 10 }, "pagination": { "page": 61, "page_size": 10, "total_count": 5758, "total_pages": 576, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=62&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=60&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T06:54:40.770Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04148430", "title": "A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Cell ALL", "B-Cell Lymphoma", "B-cell Non Hodgkin Lymphoma" ], "interventions": [ { "name": "Anakinra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2019-10-30", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • New York, New York", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04148430" }, { "nct_id": "NCT00540007", "title": "Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2007-09-06", "completion_date": "2016-09-01", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 5, "location_summary": "St Louis, Missouri • Hackensack, New Jersey • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00540007" }, { "nct_id": "NCT00460421", "title": "A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" }, { "name": "Total Body irradiation", "type": "RADIATION" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Swedish Orphan Biovitrum", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "16 Years", "sex": "ALL", "summary": "1 Year to 16 Years" }, "enrollment_count": 27, "start_date": "2006-08", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2014-12-05", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 7, "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00460421" }, { "nct_id": "NCT04685616", "title": "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Involved site radiotherapy", "type": "RADIATION" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Haematopoietic growth factor", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University College, London", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 1042, "start_date": "2022-04-14", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 3, "location_summary": "Stanford, California • Miami, Florida • New York, New York", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04685616" }, { "nct_id": "NCT01363817", "title": "Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute T-cell", "Precursor T-Cell Lymphoblastic Lymphoma" ], "interventions": [ { "name": "BMS-906024", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2011-09-28", "completion_date": "2018-02-07", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363817" }, { "nct_id": "NCT06634589", "title": "A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Malignancy", "Relapsed Cancer", "Refractory Cancer", "B-cell Lymphoma" ], "interventions": [ { "name": "Tacabrutideg", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2024-11-27", "completion_date": "2029-12-02", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06634589" }, { "nct_id": "NCT00582725", "title": "R-CHOP + GM-CSF for Previously Untreated LCL in Elderly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "R-CHOP+GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 38, "start_date": "2002-03", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2019-12-13", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582725" }, { "nct_id": "NCT04225676", "title": "Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 5, "start_date": "2020-10-19", "completion_date": "2021-10-19", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 4, "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Missouri + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225676" }, { "nct_id": "NCT06934382", "title": "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Acute Lymphoblastic Leukemia/Lymphoma" ], "interventions": [ { "name": "Allogeneic anti-CD7 CAR-T cells (BEAM-201)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stephan Grupp MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "0 Years to 29 Years" }, "enrollment_count": 33, "start_date": "2025-04-29", "completion_date": "2031-05-30", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06934382" }, { "nct_id": "NCT00134017", "title": "Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Months to 65 Years" }, "enrollment_count": 142, "start_date": "2004-06", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-10-31T06:54:40.770Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134017" } ] }